Dean Foods, CGG Veritas, Ralcorp Holdings and Onyx Pharmaceuticals

CHICAGO--([ BUSINESS WIRE ])--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List a" Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Dean Foods (NYSE: [ DF ])and CGG Veritas (NYSE: [ CGV ]). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Ralcorp Holdings, Inc. (NYSE: [ RAH ]) and Onyx Pharmaceuticals, Inc. (Nasdaq: [ ONXX ]). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: [ http://at.zacks.com/?id=92 ].

"Earnings estimate revisions are the most powerful force impacting stock prices."

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why DF and CGV have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

Dean Foods (NYSE: [ DF ]) announced first-quarter earnings of 23 cents per share on May 10 that missed analystsa� expectations by almost 18%. Year over year earnings decreased 56%. The Zacks Consensus Estimate for the current year moved down 2 cents to $1.05 per share in the last 30 days as 3 analysts out of 14 slashed forecasts. Next yeara�s estimate slipped 3 cents to $1.20 per share in the same period.

CGG Veritas (NYSE: [ CGV ]) swung to a first-quarter loss of 2 cents per share last month while the Zacks Consensus Estimate was pegged at a profit of 8 cents. The company earned 46 cents per share in the corresponding quarter a year ago. The full-year average forecast dropped a penny to 60 cents per share over the past month as one analyst out of 4 cut back on projections.

Here is a synopsis of why RAH and ONXX have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;

Ralcorp Holdings, Inc. (NYSE: [ RAH ]) posted second-quarter earnings of $1.12 per share on May 6 that fell 3% short the average forecast. The Zacks Consensus Estimate for 2010 decreased 3 cents to $4.86 per share in the last 30 days as 2 out of 10 analysts revised downward. The following yeara�s estimate slid 4 cents to $5.35 per share during that time, reflecting cuts by 2 out of 9 analysts.

Onyx Pharmaceuticals, Inc. (Nasdaq: [ ONXX ]) reported a first-quarter loss of 10 cents per share on May 4, compared with analystsa� expectations for a profit of one cent. For 2010, the Zacks Consensus Estimate stands at a loss of 4 cents per share, a penny worse than last montha�s forecast. During that time, next yeara�s estimate declined by a couple of cents to 30 cents per share.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; aZacks Rank Guide: Harnessing the Power of Earnings Estimate Revisionsa is available to provide this insightful background. Download a free copy now to prosper in the years to come at [ http://at.zacks.com/?id=93 ].

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank Stocks have generated an average annual return of +27%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (-0.9% versus +9%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.

Zacks aProfit from the Prosa e-mail newsletter offers continuous coverage of Zacks Rank Buy stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=94 ].

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=95 ].

Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ].

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

N@N

Dean Foods, CGG Veritas, Ralcorp Holdings and Onyx Pharmaceuticals